



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, PC. 20231, on March 6,1996.

Ann Lauber

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Sarah B. Noonberg and C. Anthony Hunt

Serial No.: 08/324,001

Filing Date: October 13, 1994

For: IN VIVO OLIGONUCLEOTIDE

GENERATOR, AND METHODS OF

TESTING THE BINDING AFFINITY OF

TRIPLEX FORMING

OLIGONUCLEOTIDES DERIVED

THEREFROM

Examiner: J. Martinell

Group Art Unit: 1804

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Box Non-Fee Amendment Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The undersigned hereby states that the content of the attached papers and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required as a result of this statement, applicants petition for any required relief including



extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due to our <u>Deposit Account No. 03-1952</u>. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 6, 1996

Respectfully submitted,

David L. Bradfute


Registration No. 39,117

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (415) 813-5710 Facsimile: (415) 494-0792





NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING ** NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

	/
۳	1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
□ App	7. Other: licant must provide: DO NOT REMOVE
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
Ш	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For	questions regarding compliance with these requirements, please contact:
For	Rules Interpretation, call (703) 308-1123

Please return a copy of this notice with your response.

For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856